Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European...
-
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion...
-
New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degenerationIn the experimental allergic uveitis (EAU) disease model nomacopan reduced Th17 effector...
-
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BPThe Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to...
-
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded access programFollowing initial proof of...
-
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease...
-
NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
-
NEW YORK and LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
-
International clinical development program of nomacopan for the potential treatment of COVID-19 pneumonia announcedPivotal Phase III study in patients with bullous pemphigoid (BP) expected to start H1...
-
Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil Proposed multi-center U.S. randomized clinical program in regulatory submission following...